首页> 外国专利> COMBINATION OF BEVACIZUMAB AND 2,2-DIMETHYL-N-((S)-6-OXO-6,7-DIHYDRO - 5H-DIBENZOB,DAZEPIN-7-YL)-N'-(2,2,3,3,3-PENTAFLUORO-PROPYL)-MALONAMIDE FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

COMBINATION OF BEVACIZUMAB AND 2,2-DIMETHYL-N-((S)-6-OXO-6,7-DIHYDRO - 5H-DIBENZOB,DAZEPIN-7-YL)-N'-(2,2,3,3,3-PENTAFLUORO-PROPYL)-MALONAMIDE FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

机译:贝伐单抗和2,2-二甲基-N-((S)-6-OXO-6,7-二氢-5H-二苯并[B,D] AZEPIN-7-YL)-N'-(2,2, 3,3,3-五氟-丙基)-丙二酰胺用于治疗增生性疾病

摘要

The present invention relates to a combination therapy of 2,2-dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N'-(2,2,3,3,3-pentafluoro-propyl)-malonamide, or a pharmaceutically-acceptable salt thereof, and bevacizumab for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example a brain tumor.
机译:本发明涉及2,2-二甲基-N-(((S)-6-氧代-6,7-二氢-5H-二苯并[b,d]氮杂-7-基)-N'-的联合疗法。 (2,2,3,3,3-五氟丙基)-丙二酰胺或其药学上可接受的盐和贝伐单抗,用于治疗患有增生性疾病,特别是实体瘤,例如脑瘤的患者。

著录项

相似文献

  • 专利
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号